A postmarketing safety programme for generic ticlopidine is being considered by the US FDA

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 1999年 / 753卷 / 1期

关键词：

Public Health; Neutropenia; Thrombocytopenia; Monitoring Programme; Purpura;

D O I：

10.2165/00128415-199907530-00001

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：2 / 2

相关论文

共 50 条

[21] FDA: Approval of generic drug reversed by US court of appeals
Beliveau, S
[J]. JOURNAL OF LAW MEDICINE & ETHICS, 2002, 30 (01): : 120 - 122
[22] US FDA warns that Ocaliva is being incorrectly dosed
[J]. Reactions Weekly, 2017, 1672 (1) : 9 - 9
[23] US FDA reviewing safety of ezetimibe/simvastatin
[J]. Reactions Weekly, 2008, 1217 (1) : 2 - 2
[24] Update on the Office of Drug Safety at the US FDA
[J]. Reactions Weekly, 2004, 1015 (1) : 3 - 4
[25] US FDA to review telithromycin safety and labelling
[J]. Reactions Weekly, 2006, 1086 (1) : 2 - 2
[26] US lawmakers tackle safety reforms at the FDA
Zwillich, Todd
[J]. LANCET, 2007, 369 (9578): : 1989 - 1990
[27] US FDA reviewing safety of TNF antagonists
[J]. Reactions Weekly, 2008, 1206 (1) : 2 - 2
[28] US FDA panel queries safety of gelatin
Ault, A
[J]. LANCET, 1997, 349 (9061): : 1305 - 1305
[29] CLINICAL PHARMACOLOGY POSTMARKETING STUDIES: A US FDA EVALUATION OF KNOWLEDGE GAPS AND TRANSLATION INTO LABELING.
Ridge, S.
Guinn, D.
Fletcher, E. Pfuma
Zineh, I.
Madabushi, R.
Ramamoorthy, A.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S66 - S67
[30] Pentosan associated retinal pigmentary changes: FDA's perspective on an emerging postmarketing safety finding
Lardieri, Allison
Konkel, Karen
McCulley, Lynda
Jones, S. Christopher
Moeny, David
Nguyen, Christine
Sewell, Catherine
Chambers, Wiley
Ajao, Adebola
[J]. INTERNATIONAL UROGYNECOLOGY JOURNAL, 2021, 32 (11) : 2891 - 2897

← 1 2 3 4 5 →